Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 6/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085302 | 0.88 | ADORA3 (0.41) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL25817348 | 0.82 | ADORA3 (0.46) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL3202684 | 0.79 | MPO (0.44) | CYP1A2MEN1KMT2AHTR1ADRD2 | |
| SCHEMBL3746600 | 0.77 | CYP1A2 (0.39) | ADORA3ADORA2BLMNADAOCYP1A2 | |
| SCHEMBL3207595 | 0.77 | KDM4E (0.39) | DAOCYP1A2MEN1KMT2APOLB | |
| SCHEMBL3733140 | 0.76 | DAO (0.38) | ADORA3DAOCYP1A2MEN1KMT2A | |
| SCHEMBL3210120 | 0.76 | KDM4E (0.49) | LMNAMEN1KMT2A | |
| SCHEMBL13015485 | 0.75 | DAO (0.48) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL2085200 | 0.74 | POLB (0.37) | DAOCYP1A2MEN1KMT2APOLB | |
| SCHEMBL2085441 | 0.74 | CSNK2A2 (0.37) | LMNADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163935-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8039500-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-02-25 | — | — | US | disclosed |
| US-20090312383-A1 | Fused Heterocyclic Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | CRHR1, CRHR2, CRH | ADORA3 135/4885ADORA2A 409/4885ADORA2B 370/4885 |
| US-20090312383-A1 | Fused Heterocyclic Compounds | NPY4R, CRHR1, CNR1 | ADORA3 295/4885ADORA2A 658/4885ADORA2B 497/4885 |
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | HRH4, SSTR5, CNR1 | ADORA3 216/4885ADORA2A 476/4885ADORA2B 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.